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Abstract: Adequate glycemic control in type 2 diabetes remains a difficult but achievable goal. 
The development of new classes of glucose-lowering medications, including in   particular the 
incretin-based therapies, provides an opportunity to utilize combinations of   medications which 
target multiple physiologic abnormalities in type 2 diabetes. Complementary   combination therapy 
with sitagliptin–metformin lowers glucose via enhancement of insulin secretion,   suppression of 
glucagon secretion, and insulin sensitization. Use of this combination in diabetes management 
will provide a greater degree of glycosylated hemoglobin-lowering than that seen with the use 
of either drug as monotherapy, is unlikely to cause significant hypoglycemia, and is generally 
associated with weight loss. The effectiveness, tolerability, and potential cost savings associ-
ated with the use of sitagliptin–metformin combination therapy make this an attractive option 
in diabetes management. The possible beneficial effects of this therapy on beta cell function, as 
well as its cardiovascular impact, remain inadequately explored but are of significant interest.
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Current perspective on treatment  
of type 2 diabetes
Because the number of individuals affected by diabetes is continuing to increase 
worldwide, the need for effective management assumes ever greater urgency. In 
2007, it was estimated that 7.8% of the US population was affected by diabetes, with 
the global number of affected individuals likely to exceed 220 million.1,2 Although 
glycemic control has been shown to minimize the development and progression of 
diabetes-related complications, it remains elusive for many.3 The National Health and 
Nutrition Examination Survey 2003–2004 found that only 57.1% of patients with 
diabetes had a glycosylated hemoglobin (HbA1C) level below the current treatment 
target of 7.0%.4 Despite the improvement from 35.8% at HbA1C goal in the 1999–2000 
survey, almost half of individuals with type 2 diabetes remain suboptimally managed. 
The challenges encountered in the achievement and maintenance of adequate glycemia 
are many, due in large part to the complex pathophysiology which contributes to the 
development of type 2 diabetes. Metabolic abnormalities including insulin resistance, 
at least relative insulin deficiency, and glucagon excess must be considered when 
prescribing effective glucose-lowering therapies.
Recommendations regarding the institution and intensification of antihypergly-
cemic therapy have become more aggressive in recent years. Reliance on lifestyle 
modification alone has been discouraged, because this approach has not been 
found likely to accomplish either adequate or durable glycemic control for most.5 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Initiation of glucose-lowering medication at the time of 
diabetes diagnosis, generally in the form of metformin, has 
been suggested.5 Although this may improve glycemic con-
trol early on in the course of the condition, many traditionally 
used glucose-lowering medications (including metformin) 
have not been found to alter substantially the progressive 
deterioration in beta cell function and glycemia that occurs 
in type 2 diabetes.6 Nonadherence to prescribed therapies, 
often due to cost, inconvenience, medication side effects, 
and/or regimen complexity, may also present a challenge to 
glycemic control. Furthermore, diabetes care providers may 
fail to implement effective therapies due simply to clinical 
inertia or perhaps a poor understanding of the expected 
potency or durability of the glucose-lowering therapies that 
they prescribe.
On a more positive note, the variety of antihyperglycemic 
medications now available may permit greater individualiza-
tion of therapy, and perhaps more successful therapy, than 
had previously been possible. Newer classes of medications, 
particularly those which work via the incretin pathway, 
achieve glucose lowering without the risk of weight gain 
or hypoglycemia conveyed by more traditional therapies, 
such as insulin or sulfonylureas. Because many agents with 
differing mechanisms of action are now available, comple-
mentary combinations of these medications may permit 
glucose lowering in an effective and well tolerated fashion. 
Several studies have demonstrated that combinations of dif-
ferent classes of oral agents are more effective in glucose 
lowering than are maximal doses of a single drug, leading to 
recommendations by many authors that combination thera-
pies be considered early or initially in the management of 
type 2 diabetes.7–10 For example, the American Association 
of Clinical Endocrinologists suggests initial combination 
therapy for patients with an HbA1C in the range of 7%–8% 
at the time of diabetes diagnosis.11 In addition to targeting 
multiple metabolic abnormalities underlying type 2 diabetes, 
combination therapies may result in improved adherence 
due to the smaller number of pills needed to be taken daily, 
and in some cases a reduction in overall medication costs. 
Furthermore, combinations of less than maximal doses of 
medications may permit effective glucose lowering with a 
minimization of the side effects associated with each indi-
vidual drug class. Ideally, combination therapies should be 
well tolerated, convenient to take, have few contraindications, 
have a low risk of hypoglycemia and weight gain, and be 
reasonably effective over both the short and long term. This 
article will review the available data regarding the effective-
ness, safety, and utility of fixed combinations of metformin 
and the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin 
in the treatment of type 2 diabetes.
Mechanisms of action  
and pharmacology
Sitagliptin
Sitagliptin is an orally administered agent which exerts its 
glucose-lowering effects via inhibition of the activity of the 
DPP-4 enzyme. This enzyme, in addition to circulating in a 
soluble form in plasma, is expressed in a variety of tissues 
including the liver, kidney, lung, and lymphocytes.12 DPP-4 
is responsible for the rapid degradation of the incretin 
hormones, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP), which are released 
from the gut in response to food intake. The active intact 
forms of GLP-1 and GIP both stimulate insulin secretion in 
a glucose-dependent fashion; additionally, GLP-1 contributes 
to glucose homeostasis via regulation of gastric emptying and 
glucose-dependent suppression of glucagon secretion.13 Indi-
viduals with type 2 diabetes are deficient in GLP-1 and have 
diminished responsiveness to GIP.13–15 Sitagliptin therapy 
in individuals with type 2 diabetes increases levels of and 
prolongs the half-lives of the active intact incretin hormones; 
these, in turn, lower glucose via enhancement of the insulin 
response to glucose and a decrease in glucagon secretion.16 
The likelihood of hypoglycemia due to DPP-4 inhibitor 
monotherapy is low because the incretin hormones do not 
exert glucose-lowering effects when glucose levels are below 
normal.
Sitagliptin is available in an oral tablet which may be 
administered with or without food. It is highly selective for 
DPP-4, with significantly greater affinity for that enzyme 
than for the related enzymes DPP-8 and DPP-9.17 Administra-
tion of sitagliptin rapidly inhibits the activity of DPP-4 in a 
dose-dependent fashion. Doses of 50 mg and 100 mg inhibit 
the activity of the enzyme by 80% over 12 and 24 hours, 
respectively. This degree of inhibition yields a two- to 
three-fold increase in active GLP-1 levels, and is the level of 
inhibition at which near maximal glucose lowering is seen. In 
individuals with type 2 diabetes, sitagliptin therapy exerts its 
glucose-lowering effects via increased insulin secretion and 
suppression of glucagon release. The majority of the admin-
istered drug is excreted unchanged in the urine via active 
tubular secretion.17,18 Sitagliptin is minimally metabolized 
prior to excretion and does not appear to inhibit or induce 
cytochrome P450 enzymes, making the potential for adverse 
interactions with other medications low. No significant altera-
tions in the pharmacokinetics of   rosiglitazone, glyburide, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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or metformin are known to occur following sitagliptin 
administration.16,18 The usual recommended daily dose of 
sitagliptin is 100 mg; however, because renal insufficiency 
increases drug exposure, the dose should be reduced in indi-
viduals with modest or severe renal dysfunction. The recom-
mended daily dose is 50 mg for patients with a creatinine 
clearance 30–50 mL/min and 25 mg daily for patients with a 
creatinine clearance ,30 mL/min. Renal function should be 
monitored periodically in patients using sitagliptin in order 
to ensure appropriate medication dosing.19
Metformin
Metformin, an inexpensive oral antihyperglycemic agent, 
exerts its glucose-lowering effects primarily through 
increased hepatic insulin sensitivity and the resultant sup-
pression of hepatic glucose output.20 Metformin may also 
modestly enhance glucose uptake in peripheral tissues and 
increase glucose metabolism in the splanchnic bed.21 Inter-
estingly, administration of metformin to obese subjects has 
been found to increase levels of active GLP-1 via mecha-
nisms other than DPP-4 inhibition. Direct stimulation of 
GLP-1 secretion, or perhaps a reduction in DPP-4 secretion, 
is thought to be responsible for this phenomenon.22,23 Because 
metformin does not exert its effects through a direct increase 
in insulin secretion, the likelihood of hypoglycemia induced 
by metformin monotherapy is also quite low.
Metformin is 50%–60% orally bioavailable. Admin-
istration with food may decrease absorption, although the 
clinical significance of this is unknown. It is minimally 
protein-bound, and has few drug interactions other than that 
seen with coadministration of cimetidine, which increases 
metformin levels by up to 40%. The drug has an elimination 
half-life of approximately six hours, and is generally dosed 
2–3 times daily. However, an extended-release preparation 
is available which may be administered once a day. A daily 
dose of 500 mg three times daily will exert 85% of the 
maximal glucose-lowering effect, but doses up to 2000 mg 
daily may be prescribed.21,24 Metformin is not metabolized 
prior to its complete excretion in the urine, thus decreases in 
renal function will reduce clearance of the medication. Met-
formin accumulation has been associated with lactic acidosis. 
Although this complication is uncommon, the condition is 
fatal 50% of the time.25
Rationale for use of a  
sitagliptin–metformin combination
As outlined in the preceding sections, the differing mecha-
nisms of action of sitagliptin and metformin would be 
expected to have additive effects upon glucose lowering in 
type 2 diabetes. The three main defects in diabetes, which 
include impaired insulin secretion, insulin resistance, and 
glucagon excess, will all be targeted by such a combination 
of medications. Although both metformin and sitagliptin 
monotherapy have been found to increase GLP-1 levels, this 
appears to occur through different physiologic pathways. 
Indeed, coadministration of sitagliptin–metformin to indi-
viduals with type 2 diabetes has been found to result in GLP-1 
elevation in excess of that seen with administration of either 
drug alone.27 The complementary mechanisms of action, lack 
of adverse pharmacologic interactions, and limited potential 
for hypoglycemia associated with the two medications make 
this an attractive therapeutic combination. Fixed combination 
tablets are available in doses of 50 mg sitagliptin + 500 mg 
metformin or 50 mg sitagliptin + 1000 mg metformin.19
Efficacy of sitagliptin–metformin 
combination therapy
Data from published trials evaluating the efficacy of 
sitagliptin–metformin combination therapy are summarized in 
Table 1. Results from eight large, randomized, pharmaceutical 
industry-sponsored trials have been published since 2006. 
Four of these trials utilized placebo controls, while four 
included therapy with an active comparator.
Charbonnel et al performed a multinational, double-blind, 
parallel-group study that enrolled 701 predominantly white male 
subjects, with a mean age of 54 years and a mean baseline HbA1C 
of 8.0% on metformin alone at a minimum dose of 1500 mg 
daily.28 Subjects were randomly assigned to additional therapy 
with either placebo or sitagliptin 100 mg daily. At 24 weeks, 
sitagliptin–metformin therapy resulted in a placebo-subtracted 
HbA1C reduction of 0.65%. Combination therapy resulted in 
significantly more subjects achieving an HbA1C of less than 7% 
when compared with metformin monotherapy, and significantly 
lowered fasting plasma glucose. Sitagliptin–metformin 
combination therapy was associated with greater increases 
in C-peptide and homeostasis model assessment of beta cell 
function (HOMA β) than seen with metformin therapy alone, 
suggestive of enhancement in beta cell function. Furthermore, a 
reduction in the proinsulin/insulin ratio seen only in the combi-
nation therapy group may represent an improvement in insulin 
processing conveyed by this treatment. Mean body weight 
decreased significantly from baseline in both treatment groups 
(−0.6 to −0.7 kg) without any significant between-group dif-
ferences. Rates of discontinuation and the incidence of adverse 
drug-related events (including hypoglycemia and gastrointestinal 
side effects) were similar in the two groups.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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In another large placebo-controlled multinational trial, 
Goldstein et al randomized 1091 men and women with a 
mean baseline HbA1C of 8.8% to one of six daily treatments, 
ie,   sitagliptin 100 mg + metformin 2000 mg, sitagliptin 
100 mg + metformin 1000 mg, metformin 2000 mg, met-
formin 1000 mg (all dosed in evenly divided, twice-daily 
doses), sitagliptin 100 mg, or placebo.29 At 24 weeks, when 
compared with placebo, the active treatments significantly 
reduced HbA1C by 2.07%, 1.57%, 1.30%, 0.99%, and 
0.83%, respectively. The proportion of subjects achieving 
an HbA1C , 7% was significantly higher in the sitagliptin 
100 mg + metformin 2000 mg group than in the sitagliptin 
100 mg + metformin 1000 mg group. In an open-label, high-
HbA1C cohort, a group of patients with mean baseline HbA1C 
11.2% treated with sitagliptin 100 mg + metformin 2000 mg 
achieved a mean HbA1C lowering of 2.9%. With the exception 
of sitagliptin monotherapy, which resulted in no significant 
change in body weight, all active treatment groups experi-
enced significant reductions in body weight relative to baseline 
(−0.6 to −1.3 kg; P , 0.005). The incidence of hypoglycemia 
and gastrointestinal side effects were similar for all active 
therapies. After the main trial was completed, 885 of 1091 
subjects entered a 30-week continuation trial and remained 
on their previously assigned active oral treatments.30 Those 
in the placebo group were switched to metformin 2000 mg 
daily (results from this switch group were excluded from the 
final analysis). Glycemic response was durable over time 
across the active treatment groups. In the all-patients-treated 
analysis at week 54, the mean HbA1C reductions from base-
line were: sitagliptin 100 mg + metformin 2000 mg, 1.8%; 
sitagliptin 100 mg + metformin 1000 mg, 1.4%; metformin 
2000 mg, 1.3%; metformin 1000 mg, 1.0%; and sitagliptin 
100 mg, 0.8%. The proportion of subjects with HbA1C , 7% 
in the above groups were 67%, 48%, 44%, 25%, and 23%, 
respectively. Mean decrease in weight from baseline was 0.7 
to 1.7 kg in all groups other than the sitagliptin monotherapy 
group, in which mean weight did not change significantly. As 
in the initial trial, the incidence of hypoglycemia and gastro-
intestinal side effects was similar among the groups.
In a third multinational, placebo-controlled trial, Raz 
et al randomly assigned 190 men and women (mean age 55 
years, mean HbA1C 9.2%) on a stable dose of $1500 mg 
metformin daily to the addition of either placebo or sitagliptin 
100 mg daily.31 At 30 weeks, the sitagliptin–metformin group 
achieved a 1.0% placebo-subtracted HbA1C reduction. Weight 
decreased by 0.5 kg in both groups. Study discontinuation 
and clinical adverse events (including hypoglycemia and 
gastrointestinal side effects) were similar in the two groups. 
While the percentage of subjects with laboratory adverse 
events was higher in the sitagliptin–metformin group (15%) 
compared with the placebo–metformin group (4.3%), the 
only discernible pattern was a decrease in hemoglobin which 
occurred in subjects with illnesses that predisposed to blood 
loss. None of the laboratory adverse events were considered 
serious or drug-related.
There have been four randomized trials comparing 
sitagliptin–metformin with active comparators, including 
the additions of glipizide, rosiglitazone, exenatide, or lira-
glutide to baseline metformin therapy. First, in a 52-week 
multinational, double-blind, noninferiority trial, 1172 men 
and women (mean age 57 years, mean HbA1C 7.7%) receiv-
ing metformin $1500 mg daily were randomized in a 1:1 
ratio to the addition of sitagliptin 100 mg daily or glipizide 
(mean within-trial dose 10.5 mg daily).32 In the per protocol 
analysis, both groups experienced a mean HbA1C lowering 
of 0.67%. HbA1C lowering to ,7% occurred in 63% of sub-
jects in the sitagliptin–metformin group and in 59% in the   
glipizide–metformin group. The sitagliptin–metformin 
group had a significant mean weight change of −1.5 kg, 
while a weight gain of 1.1 kg was experienced by the 
glipizide–metformin group. The proportion of subjects 
experiencing hypoglycemia was significantly higher in the 
glipizide–metformin group than in the sitagliptin–metformin 
group (32% and 5%, respectively). Notably, 202 subjects in 
the sitagliptin–metformin group discontinued treatment due 
to “lack of efficacy”, compared with 172 in the glipizide–
metformin group. Those subjects who discontinued due to 
lack of efficacy had a higher mean HbA1C at baseline than did 
those who completed the study (8.6% versus 7.5%).
A second active comparator trial was performed by 
Scott et al who examined 273 subjects (60% white and male, 
mean age 55 years, mean HbA1C 7.7%) on metformin therapy 
($1500 mg daily), randomizing them to the addition of either 
placebo, sitagliptin 100 mg daily, or rosiglitazone 8 mg 
  daily.33 At 18 weeks, both active treatment groups had signifi-
cant decreases in HbA1C from baseline; −0.51% and −0.57% 
in the sitagliptin–metformin and rosiglitazone–metformin 
groups, respectively. The proportion of patients experiencing 
A1C lowering to , 7% was greater in the sitagliptin–metformin 
(55%) and rosiglitazone–metformin (63%) groups when 
compared with placebo–metformin (38%). Mean weight 
increased in the rosiglitazone–metformin group by 1.5 kg, 
whereas those treated in the sitagliptin–metformin and 
placebo–metformin groups lost weight (−0.4 kg and −0.8 kg, 
respectively). Both active drugs were well tolerated with no 
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adverse effects. The proportions of subjects who discontin-
ued the study were higher in the sitagliptin–metformin and 
  placebo–metformin groups (10% and 9%, respectively) when 
compared with the rosiglitazone–metformin group (2%). 
Adverse experiences (3%) and withdrawal of consent (4%) 
were the most common reasons cited for discontinuation in 
the sitagliptin–metformin group.
In a multicenter, randomized, double-dummy, crossover 
Phase IV trial in 61 men and women (mean age 54 years, mean 
HbA1C 8.5%), DeFronzo et al compared sitagliptin–metformin 
with exenatide–metformin.34 Subjects who were on a stable 
dose of metformin were randomized to either exenatide or 
sitagliptin for two weeks and crossed over to the alternative 
therapy for another two weeks. The primary outcome was 
two-hour postprandial glucose. Exenatide–metformin lowered 
two-hour postprandial glucose to 166 mg/dL compared with 
210 mg/dL in the sitagliptin–metformin group. This differ-
ence followed the drug after crossover. Exenatide–metformin 
resulted in greater mean weight loss (−0.8 kg) than did 
sitagliptin–metformin (−0.3 kg). Caloric intake (assessed 
in 25 subjects) decreased significantly with exenatide–
metformin therapy as compared with   sitagliptin–metformin, 
with mean changes from baseline of −134 and +130 kcal/day, 
respectively. Gastrointestinal side effects of mild to moderate 
severity were experienced in both the exenatide–metformin 
and sitagliptin–metformin groups.
Pratley et al performed a parallel-group, open-label trial in 
Europe, the US, and Canada to assess the efficacy and safety 
of the addition of either liraglutide or sitagliptin to metformin 
therapy.35 In total, 665 men and women, with a mean age of 
55 years and a mean HbA1C of 8.5%, were randomized to 
receive one of two doses of liraglutide (1.2 mg or 1.8 mg sub-
cutaneously daily) or sitagliptin 100 mg daily for 26 weeks. 
Subjects treated with either 1.2 mg or 1.8 mg of liraglutide 
experienced significantly greater HbA1C lowering compared 
with sitagliptin (mean HbA1C decreases of 1.24%, 1.5%, and 
0.9%, respectively). Mean waist circumference decreased by 
2.69 cm, 2.63 cm, and 1.12 cm in those receiving liraglutide 
1.8 mg + metformin, liraglutide 1.2 mg + metformin, and 
sitagliptin–metformin, respectively. All subjects experienced 
weight loss, with mean decreases of 2.86 kg, 3.38 kg, and 
0.96 kg, reported in the three respective groups.
Nonglycemic effects
Each trial discussed earlier examined markers of insulin 
resistance, such as the quantitative insulin sensitivity check 
index or homeostasis model assessment of insulin   resistance 
(HOMA-IR), as well as HOMA-β or other markers of beta 
cell function. In general, sitagliptin–metformin therapy 
improved measures of beta cell function to a greater degree 
than did metformin alone, whereas administration of 
exenatide or liraglutide tended to outperform sitagliptin on 
similar measures. No significant changes in estimates of 
insulin resistance or insulin sensitivity were associated with 
sitagliptin exposure.28–35
Safety and tolerability
Overall, drugs in the DPP-4 inhibitor class, and sitagliptin 
specifically, are well tolerated. There is little independent 
causation of hypoglycemia; however, hypoglycemia may 
occur when sitagliptin is combined with medications, such 
as sulfonylureas or insulin.36,37 Sitagliptin is generally consid-
ered weight-neutral, but the combination of sitagliptin and a 
sulfonylurea may promote weight gain. Sitagliptin does not 
appear to attenuate the weight loss effects associated with 
metformin therapy significantly. There does appear to be a 
slightly increased risk for nasopharyngitis and headache 
associated with sitagliptin use. However, in clinical trials, 
these side effects were unlikely to be severe or result in 
discontinuation of the medication.37
Hypersensitivity events temporally related to initiation 
of sitagliptin, including anaphylaxis, angioedema, and 
exfoliative skin conditions, have occurred in the postmar-
keting period. Continued use of or re-exposure to sitagliptin 
is contraindicated in patients who have experienced these 
hypersensitivity reactions.38 Additionally, there have been 
postmarketing reports of pancreatitis occurring in patients 
treated with sitagliptin, as well as in patients using the GLP-1 
analog, exenatide. A subsequently published retrospective 
review of hospital records did not reveal an increased risk 
of hospitalization for pancreatitis in patients using sitaglip-
tin or exenatide compared with those using metformin or 
glipizide for diabetes therapy.39 Further study is needed to 
clarify whether the incretin-related diabetes medications 
are truly causative, or if these cases might simply be due 
to use of the medications in a population which is already 
at greater than average risk for pancreatitis. The US Food 
and Drug Administration recommends that physicians warn 
patients about the potential risk as well as the symptoms of 
pancreatitis, and that sitagliptin be discontinued if symptoms 
or signs of pancreatitis develop.19
The most common adverse effects of metformin are nausea, 
vomiting, flatulence, and diarrhea, which can occur in up to 
20% of patients.40 As previously noted,   metformin-  associated 
lactic acidosis may rarely occur, generally reported as 
approximately 0.03 cases per 1000 patient-years.19 The true Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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incidence of metformin-associated lactic acidosis is unclear. 
One recent systematic review, encompassing nearly 50,000 
patient-years of use in 206 clinical trials, found no cases of 
either fatal or nonfatal lactic acidosis to have occurred in 
conjunction with metformin use.25 Still, metformin use is 
contraindicated in the setting of renal dysfunction (males with 
a creatinine $1.5 and females with a creatinine $1.4), or in 
those at risk for lactic acidosis due to hypoperfusion of renal 
or other tissues. Individuals with acute or chronic metabolic 
acidosis, significant hepatic dysfunction, or acute or unstable 
congestive heart failure are not considered candidates for 
metformin use. The drug should be temporarily discontinued 
prior to surgery or intravenous contrast administration, and 
is not recommended for use in individuals aged older than 
80 years who do not have a normal creatinine clearance.21,24 
Some authors have suggested that lower doses of met-
formin may be safely used in individuals with compromised 
renal function, but this has not been met with widespread 
acceptance.26
The most common adverse reactions in patients taking 
both sitagliptin and metformin were diarrhea, upper respi-
ratory tract infection, and headache.19 Contraindications 
to the use of sitagliptin–metformin include the contrain-
dications listed for both of the individual medications. Of 
note, the precautions regarding metformin use in patients 
with renal dysfunction also apply to combination therapy. 
Sitagliptin–metformin combination therapy has not been 
studied in women who are pregnant or lactating, or in 
pediatric populations, thus its use cannot be recommended 
for these patients. Finally, there have been no clinical stud-
ies establishing conclusive evidence of macrovascular risk 
reduction with the use of sitagliptin–metformin or any other 
antidiabetic drugs.19
Quality of life, satisfaction,  
and acceptability
Combining sitagliptin and metformin in a single pill has 
the potential to simplify a patient’s treatment regimen. 
Taken twice daily, this therapy does not have the dis-
comfort or inconvenience associated with multiple daily 
insulin injections. Furthermore, adherence and patient 
satisfaction may increase with a regimen which includes a 
limited number of tablets taken daily. The combination of 
sitagliptin–metformin was well tolerated in clinical trials. 
The addition of sitagliptin to metformin does not appear to 
worsen the known gastrointestinal side effects associated 
with metformin monotherapy, which can often be minimized 
with slow   uptitration of dose and administration with meals. 
Although the addition of either sitagliptin or metformin 
to sulfonylurea therapy is associated with some degree 
of hypoglycemia, this complication is rarely seen with 
sitagliptin–metformin combination therapy. The effect of 
this combination on body weight is generally favorable. In 
clinical trials, patients receiving sitagliptin–metformin com-
bination therapy generally maintained their weight or lost an 
average of up to 1.5 kg in weight. This is a desirable effect, 
particularly when compared with the weight gain generally 
conveyed by alternative glucose-lowering therapies, such as 
sulfonylureas, thiazolidinediones, or insulin. The clinical 
trials experienced to date suggests that patients with poorly 
controlled diabetes at baseline were somewhat more likely to 
discontinue sitagliptin–metformin due to lack of efficacy than 
were patients assigned to sitagliptin–sulfonylurea; otherwise, 
rates of drug discontinuation due to adverse events have been 
quite low.32,33 Overall, combination sitagliptin–metformin 
therapy for type 2 diabetes appears to be well tolerated and 
acceptable to patients.
Conclusion
Despite the availability of many different oral agents for the 
management of type 2 diabetes, almost half of individuals 
remain suboptimally controlled. The reasons for this are 
likely multifactorial, with some more readily remediable 
than others. The availability of effective and tolerable com-
bination therapy may permit greater numbers of patients to 
meet therapeutic goals. Several studies have demonstrated 
that combinations of different classes of oral agents are 
more effective in glucose lowering than are maximal doses 
of a single drug. Furthermore, use of metformin therapy at 
the time of diabetes diagnosis with rapid intensification of 
subsequent drug therapy has been recommended by both the 
American Diabetes Association and the European Associa-
tion for the Study of Diabetes.5 Certainly, adherence may 
be enhanced with prescription of a smaller number of pills 
which incorporate medicines of low propensity to cause 
either hypoglycemia or weight gain. In addition, potential 
reduction in medication costs with combination tablets (in 
which the generic medication is often provided at minimal 
to no additional cost) may further enhance adherence to a 
therapeutic regimen.
Clinical trials of sitagliptin–metformin have demon-
strated decreases in HbA1C ranging from 0.5% to 2.1%, 
with a significantly higher proportion of subjects lowering 
their HbA1C to less than 7% compared with metformin 
alone.20,28,29,33,34 Furthermore, this combination is associ-
ated with a mean weight loss of 0.4–1.7 kg, similar to that Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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seen with metformin alone.29,30,32–35 The risk of hypoglyce-
mia with this combination ranges from 1% to 5% and is 
equivalent to that seen with metformin monotherapy (or 
exenatide–rosiglitazone–metformin) and lower than that 
seen with a glipizide–metformin combination.32 Although 
sitagliptin treatment is not expected to convey the same 
degree of glucose lowering or the weight loss effects seen 
with exenatide or liraglutide therapy, the convenience of 
taking a medication in pill form rather than an injection may 
be preferable for many patients. Furthermore, although no 
direct comparisons have been made in clinical trials to date, 
initiation of sitagliptin–metformin therapy has been shown 
to provide HbA1C-lowering benefits similar to those reported 
in trials of exenatide or liraglutide monotherapy.41,42
Sitagliptin–metformin combination therapy may have a 
favorable impact on beta cell function. However, long-term 
studies will be needed to determine if the improvement in 
markers of beta cell function will translate into preservation 
of beta cell mass or greater durability of glycemic control 
than that seen with more traditionally prescribed therapies. 
As is required of all new antihyperglycemic therapies, the 
long-term cardiovascular safety of sitagliptin is currently 
under evaluation in TECOS (Trial to Evaluate Cardiovascu-
lar Outcomes after Treatment with Sitagliptin). Inclusion of 
a large number of patients on the combination of sitagliptin 
and metformin is expected.43 Although the data available 
from clinical trials of sitagliptin to date have not raised 
concerns about the drug’s cardiovascular safety, sitagliptin 
trials prior to TECOS were of relatively short duration, did 
not consistently enroll a high cardiovascular risk population, 
and were not designed to assess reliably the cardiovascular 
impact of sitagliptin use.44
In summary, sitagliptin and metformin exert a comple-
mentary glucose-lowering effect and represent a well toler-
ated option for patients requiring therapy for type 2 diabetes. 
This combination should play an important role in the current 
treatment algorithm for this condition.
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